Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a systematic review and meta-analysis
J. psychiatr. res; 181 (), 2025
INTRODUCTION: Schizophrenia is one of the psychiatric illnesses with a higher mortality rate. Xanomeline, an oral muscarinic receptor agonist, combined with Trospium, a pan-muscarinic receptor antagonist, represents a promising new treatment for schizophrenia that has been tested in clinical trials. Here...